139 related articles for article (PubMed ID: 32756119)
21. Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases.
Bai B; Yuan ZY; Liu DG; Teng XY; Wang SS
Chin J Cancer; 2010 Apr; 29(4):413-9. PubMed ID: 20346218
[TBL] [Abstract][Full Text] [Related]
22. Effects of Postoperative Radiotherapy on Leptomeningeal Carcinomatosis or Dural Metastasis after Resection of Brain Metastases in Breast Cancer Patients.
Ha B; Chung SY; Kim YJ; Gwak HS; Chang JH; Lee SH; Park IH; Lee KS; Lee S; Kim TH; Kim DY; Kang SG; Suh CO
Cancer Res Treat; 2017 Jul; 49(3):748-758. PubMed ID: 27809457
[TBL] [Abstract][Full Text] [Related]
23. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
Gobbini E; Ezzalfani M; Dieras V; Bachelot T; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Cleaud AL; Robain M; Courtinard C; Cailliot C; Perol D; Delaloge S
Eur J Cancer; 2018 Jun; 96():17-24. PubMed ID: 29660596
[TBL] [Abstract][Full Text] [Related]
24. Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis.
Torrejón D; Oliveira M; Cortes J; Sanchez-Olle G; Gómez P; Bellet M; Saura C; Peg V; Rovira A; Di Cosimo S
Breast; 2013 Feb; 22(1):19-23. PubMed ID: 23137566
[TBL] [Abstract][Full Text] [Related]
25. A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple-negative breast cancer.
Lin M; Jin Y; Jin J; Wang B; Hu X; Zhang J
Cancer Med; 2020 Nov; 9(22):8540-8551. PubMed ID: 32945619
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
27. Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases.
Cagney DN; Lamba N; Montoya S; Li P; Besse L; Martin AM; Brigell RH; Catalano PJ; Brown PD; Leone JP; Tanguturi SK; Haas-Kogan DA; Alexander BM; Lin NU; Aizer AA
Breast Cancer Res Treat; 2019 Jul; 176(1):171-179. PubMed ID: 30982195
[TBL] [Abstract][Full Text] [Related]
28. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
29. Differentiation of triple-negative breast cancer from other subtypes through whole-tumor histogram analysis on multiparametric MR imaging.
Xie T; Zhao Q; Fu C; Bai Q; Zhou X; Li L; Grimm R; Liu L; Gu Y; Peng W
Eur Radiol; 2019 May; 29(5):2535-2544. PubMed ID: 30402704
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
[TBL] [Abstract][Full Text] [Related]
31. Treating Brain Metastases from Breast Cancer: Outcomes after Stereotactic Radiosurgery.
Wilson TG; Robinson T; MacFarlane C; Spencer T; Herbert C; Wade L; Reed H; Braybrooke JP
Clin Oncol (R Coll Radiol); 2020 Jun; 32(6):390-396. PubMed ID: 32131980
[TBL] [Abstract][Full Text] [Related]
32. Carcinomatous meningitis secondary to transitional cell bladder cancer.
Bowen CD; Von Burton G; Bargen RC; Madonia P; Zhang S; Toledo EG; Zweig R; Pant C
South Med J; 2010 Aug; 103(8):809-12. PubMed ID: 20622726
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients.
Rades D; Lohynska R; Veninga T; Stalpers LJ; Schild SE
Cancer; 2007 Dec; 110(11):2587-92. PubMed ID: 17893909
[TBL] [Abstract][Full Text] [Related]
34. Survival following radiotherapy in young women with localized early-stage breast cancer according to molecular subtypes.
Liu QQ; Sun HF; Yang XL; Chen MT; Liu Y; Zhao Y; Zhao YY; Jin W
Cancer Med; 2019 Jun; 8(6):2840-2857. PubMed ID: 31016890
[TBL] [Abstract][Full Text] [Related]
35. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
[TBL] [Abstract][Full Text] [Related]
36. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
37. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
38. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
39. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
40. MRI based neuroanatomical segmentation in breast cancer patients: leptomeningeal carcinomatosis vs. oligometastatic brain disease vs. multimetastastic brain disease.
Mayinger M; Reibelt A; Borm KJ; Ettl J; Wilkens JJ; Combs SE; Oechsner M; Duma MN
Radiat Oncol; 2019 Sep; 14(1):170. PubMed ID: 31533742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
